S. Hammami

AB0517 Predictive factors for infection in systemic lupus erythematosus

Background its known that infection could complicate the course of systemic lupus erythematosus (SLE) because of the immune status or the long term steroids and immunosuppressors. Objectives This study was aiming at determining the prevalence of infectious complications during SLE and their predictive factors. Methods A retrospective bi-centric analyzes of 289 patients diagnosed as SLE between January 2004 and December 2016 according to the ARA criteria of 1997 was conducted. A descriptive analysis of infectious complications was first made, then a comparative study between patients with (group 1) and without (group 2) infectious complications was performed to detect predictive factors. Results Mean age was 84.6±13 years (14–72 years) with a sex ratio F/M=6. Cardiac involvement and lupus nephritis (LN) were developed in 20% of patients. About 13.75% of patients had neurological manifestations, 26.5% articular complications, 16% vascular involvement and 10% of them developed infectious complications. Eight percent of these infections were diagnosed concomitantly with the diagnosis of SLE and 92% of them after the diagnosis of lupus with an average of 25 months. About 52.9% of the patients developed more than 2 episodes of infection. The spectrum of infectious complications was: pulmonary in 33.3%, urinary in 22.2% and cutaneous in 13.9%. Tuberculosis was the most frequent infection 12.5%. Lupus flare complicated the infection in 28.6% of patients with mean SLEDAI score at 10. Comparative study between group 1 and group 2 revealed that LN, corticosteroids and immunosuppressors were associated with a high risk of infection (p=0.002, p=0.017 and p=0.034 respectively). In multivariate analysis only LN was an independent predictive factor (OR=3.5, 95% CI=1.06- 12.87, p=0.049). Conclusions Infections may complicate the course of SLE with flares presenting in 1/3 of cases. Half of the patients had more than 2 episodes of infection during their follow up. The presence of LN represents a predictive factor of such complication. Disclosure of Interest None declared

AB0592 Pulmonary artery aneurysm in behÇet's disease: retrospective monocentric tunisian study

Background Behcets disease (BD) is a chronic inflammatory disorder. Arterial inflammatory involvement includes predominantly aortic and pulmonary aneurysmal lesions, affects about 10% of patients with BD. They account for the severity of the disease and are a leading cause of death Objectives To investigate the frequency of Behcets disease with pulmonary artery aneurysm (PAA). We aimed to review PAA and other systemic involvements associated with PAA in BD and to provide a review of diagnostic techniques, treatment and prognosis Methods 243 BD patients were recruited for this study (152 men, 91 women, mean age 31.7±7 years. Diagnosis of BD was made according to the international study group for Behçets disease [International Study Group for Behçets Disease, lancet 1990; 335: 1078–80]. All patients underwent full clinical examination, routine laboratory investigations. Chest X-rays and pulmonary CT angiography were performed on all patients with pulmonary involvement. Results Eight of the patients have pulmonary aneurysm, all of them are male, mean age 32.6±13, The mean disease duration until PAA appear was 2.8±3.5 years. The main pulmonary symptoms were as follows: dyspnea 87%, cough 50%, hemoptosis: 75%, fever 37%. Other systemic involvements associated PAA are as follows: buccal (100%) and genital (75%) ophthalmic 25%, neurological 50%, cardiac 25%. 3 patients presented with Hughes Stovin syndrome. The treatment includes corticosteroids, colchicine and immunosuppressant agents (Cyclophosphamid or azathioprine), only two patients reveive coil embolization. At follow up for a median of 4 years (1 to 25 years), three patients died because they stopped their medication. Conclusions The prognosis of PAA is poorer than other lesions involved in BD, treatment (immunosuppressant agents, colchicine) seems to improve the prognosis. It is important to maintain the immunosuppressive therapy and a regular follow-up to prevent these complications References Desbois AC et al Aortic inflammatory lesions in Behçets disease Rev Med Interne. 2016 Apr;37(4):230–8. Celik S et al. Pulmonary artery aneurysms in Behçets syndrome: a review of the literature with emphasis on geographical differences. Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S54–9. Disclosure of Interest None declared